Many who had been denied the life-enhancing drug Aricept because of its price of Ł2.13 a day will now benefit. The fall in its cost comes after its patent ran out which means generic versions can now be prescribed at a cut-price 43p a day. It cannot cure

EMA's trial design hinders Eisai's Halaven reimbursement in Germany Today Francesca Bruce Eisai's end of life breast cancer drug Halaven (eribulin) offers a "hint" of "unquantifiable" additional benefit against comparators for patients unable to continue

In this article, I list 5 biopharmas that have huge upside potential, but are very high risk and have equally as large downside potential. Exposure to these stocks need careful consideration by investors. Arena Pharmaceuticals (ARNA) is a clinical-stage

—Jonathan D. Rockoff contributed to this article. In the wake of research suggesting a skin-cancer drug may have benefits in treating Alzheimer's disease, physicians and advocacy groups are getting a flurry of calls from patients seeking to use the drug

The nonprofit Hamner Institutes for Health Sciences is selling its Research Triangle Park campus for $20 million as part of a sale-and-leaseback deal. In conjunction with today's announcement of the sale to Alexandria Real Estate Equities, a California f

By Katherine Hobson Asking About Off-Label Use: Families of Alzheimer’s patients are asking physicians and advocacy groups about the off-label use of a skin-cancer drug, bexarotene, in their loved ones following a study suggesting a benefit for the drug